Janet Jill Hopkins
CIK 1997710 · View on SEC EDGAR ↗
First SEC filing: Feb. 2, 2024 · Latest: Feb. 2, 2024
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 17, 2026 | AURA | S | 20,401 | $5.06 | $103,229 | 232,284 Direct | -8.07% | Disposed | 55.5% (price as of 2026-08-21) |
| Nov. 17, 2025 | AURA | S | 17,109 | $5.42 | $92,731 | 252,685 Direct | -6.34% | Disposed | 45.2% (price as of 2026-08-21) |
| Feb. 18, 2025 | AURA | S | 2,534 | $7.75 | $19,638 | 269,794 Direct | -0.93% | Disposed | 1.5% (price as of 2026-08-21) |
| Nov. 18, 2024 | AURA | S | 11,822 | $9.36 | $110,654 | 151,693 Direct | -7.23% | Disposed | -15.9% (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 2, 2026 | AURA | Stock Option (Right to Buy) | Common Stock (160,944) | $6.14 | March 2, 2036 | 160,944 | Acquired |
| Feb. 3, 2025 | AURA | Stock Option (Right to Buy) | Common Stock (79,365) | $7.68 | Feb. 2, 2035 | 79,365 | Acquired |
| Feb. 1, 2024 | AURA | Stock Option (Right to Buy) | Common Stock (41,485) | $7.77 | Jan. 31, 2034 | 41,485 | Acquired |
| Nov. 1, 2023 | AURA | Stock Option (Right to Buy) | Common Stock (200,000) | $8.97 | Oct. 31, 2033 | 200,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
AURA
M.D.Chief Medical Officer and President of Research and Development| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $551,250 | — | — | — | $220,500 | — | $21,000 | $2,188,965 |
| 2024 | $525,000 | — | — | — | $236,250 | — | — | $1,226,076 |
| 2023 | $109,375 | $200,000 | — | — | $49,536 | — | — | $2,935,681 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.